Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Opioid-use Disorder, Pain, Acute
Interventions: HYDROmorphone Injectable Solution, Ketamine, Placebos; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Spondylolisthesis, Lumbar Spondylosis, Lumbar Radiculopathy, Lumbar Spine Instability, Synovial Cyst, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Intervertebral Discs
Interventions: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine, normal saline; Drug
Lead sponsor: John O'Toole; Other
Eligibility: 18 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malignant Neoplasms of Brain
Interventions: PEP-3-KLH conjugate vaccine, daclizumab, temozolomide, placebo, PEP-3-KLH; Biological · Drug · Other
Lead sponsor: John Sampson; Other
Eligibility: 18 Years to 120 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Autonomic Nervous System, Baroreflex, Stress, Physiological
Interventions: Cosyntropin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions: AVR-48, Placebo; Drug
Lead sponsor: AyuVis Research, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Interstitial Lung Disease
Interventions: Trans Sodium Crocetinate, Placebo; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Craniotomy, Brain Surgery
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Crohn's Disease
Interventions: abatacept, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more

Conditions: Lower Back Pain
Interventions: CNTX-3001, Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Napa, California

Conditions: Nephrectomy
Interventions: TAP block placement with placebo, Placement of block with ropivacaine; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Dengue Fever
Interventions: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 13 Years to 63 Years
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: Placebo, Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Suvankar Majumdar; Other
Eligibility: 4 Years to 21 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Volunteers, Healthy
Interventions: Recombinant human plasma gelsolin, placebo; Drug · Other
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Benign Prostatic Hyperplasia
Interventions: Tranexamic Acid (IV), Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Femoroacetabular Impingement
Interventions: regional anesthesia bupivacaine, regional anesthesia placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Incisional Pain
Interventions: TAP Catheter and Infusion of Study Solution; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: ZTI-01, Moxifloxacin 400mg, Placebo IV; Drug · Other
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Injection Fear, Injection Pain Prevention, Injection Complication
Interventions: Ethyl Chloride, Cold Saline Spray; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postoperative Pain
Interventions: Placebo, Drug .5% Ropivacaine, 20 cc of 0.25% ropivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Acute Pain Management in Patients on Opioid Replacement Therapy

Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

Stress and the Nervous System

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

The Efficacy of Intravenous Acetaminophen During Perioperative Neurosurgery Period

A Study of Abatacept in Patients With Active Crohn's Disease

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

Transversus Abdominus Plane Block

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Treatment of Orthostatic Intolerance

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

Regional Anesthesia in Hip Arthroscopy

Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

4-way Crossover QT Evaluation in Healthy Subjects

Does Ethyl Chloride Spray Work?

Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy